DSIP: Community Protocols & Reports
Aggregated community experiences, protocols, and stacking patterns
Community-Sourced Information
The protocols and reports on this page are gathered from online communities and forums. They represent anecdotal experiences, not clinical evidence. Individual results vary significantly. This information is not medical advice and should not replace consultation with a qualified healthcare provider. Always verify dosing and safety information with peer-reviewed research before making any decisions.
For peer-reviewed dosing protocols, see the clinical dosing guide.
Browse community protocols for all 130 peptides โ
๐TL;DR
- โข4 community protocols documented
- โขEvidence level: Structured Community Data
- โขBased on 80 community reports
- โข3 stacking patterns reported
Clinical vs. Community Protocol Differences
How community-reported protocols differ from clinical research protocols.
| Aspect | Clinical Approach | Community Approach | Significance |
|---|---|---|---|
| Administration Route | Early human studies used intravenous (IV) infusion of DSIP, typically at doses of 25-30 nmol/kg. Some studies also used intramuscular and intranasal administration. | Community exclusively uses subcutaneous injection, a route not studied in the published DSIP research. IV infusion is not practical for self-administration. | high The IV-to-SubQ route change significantly alters pharmacokinetics. IV infusion provides rapid systemic delivery, while SubQ absorption is slower and may produce different plasma concentration curves. |
| Dosing | Clinical studies used weight-based dosing, typically 25-30 nmol/kg IV, which translates to roughly 21-25 mcg/kg body weight. For a 70 kg person, this would be approximately 1,500-1,750 mcg. | Community uses fixed doses of 100-500 mcg subcutaneously, significantly lower than the weight-based IV doses used in clinical research. | high Community doses are substantially lower than clinical IV doses. This could reflect the different route (SubQ may have lower bioavailability), anecdotal dose-finding, or simply caution with a poorly characterized peptide. |
| Treatment Duration | Clinical studies ranged from single-dose assessments to short treatment periods (typically days to 2 weeks). Long-term studies are very limited. | Community typically uses 2-6 week cycles, with many users emphasizing the importance of cycling off to prevent dependence on exogenous DSIP for sleep initiation. | moderate Some community members report rebound insomnia after prolonged use, which supports the cycling approach even though clinical data on this phenomenon is limited. |
Compare these community approaches with published research findings.
Community Protocols
Standard Sleep Protocol
Popular- Route
- Subcutaneous
- Dose
- 100-200 mcg
- Frequency
- Once daily, 30-60 minutes before bed
- Duration
- 2-4 weeks
Most commonly reported starting dose; injected subcutaneously in the evening before bedtime
Higher-Dose Sleep Protocol
Common- Route
- Subcutaneous
- Dose
- 250-500 mcg
- Frequency
- Once daily before bed
- Duration
- 2-4 weeks
Higher dose for severe sleep issues; some users report next-day grogginess at doses above 300 mcg
Intermittent Dosing Protocol
Common- Route
- Subcutaneous
- Dose
- 100-250 mcg
- Frequency
- 3 times per week
- Duration
- 4-6 weeks
Used to minimize tolerance risk; dosed on non-consecutive evenings (e.g., Mon/Wed/Fri)
Low-Dose Stress Protocol
Niche- Route
- Subcutaneous
- Dose
- 50-100 mcg
- Frequency
- Once daily
- Duration
- 2-4 weeks
Lower doses used by those targeting stress modulation rather than sleep induction
Stacking Patterns
DSIP + CJC-1295/Ipamorelin Sleep-GH Stack
CommonCombining DSIP for improved sleep quality with GH secretagogues for enhanced growth hormone release during deep sleep phases
DSIP + Selank Sleep-Anxiety Stack
NicheDSIP for sleep induction combined with Selank for anxiety reduction in users whose insomnia has an anxiety component
Check stack compatibility and review potential side effects before combining peptides.
Unlock community dosing protocols and stacking combos
See the exact doses, routes, and schedules 80+ self-experimenters report. Free with email.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Sources
- Reddit r/Peptides|DSIP experience reports and sleep protocol discussions(accessed 2026-02-16)
- Reddit r/PeptideResearch|DSIP dosing and cycling discussions(accessed 2026-02-16)
- Muscle and Brawn|Delta-Sleep Inducing Peptide (DSIP) Latest Guide(accessed 2026-02-16)
- Innerbody|DSIP (Delta Sleep-Inducing Peptide) full rundown(accessed 2026-02-16)
- Swolverine|DSIP benefits, dosage, and risks explained(accessed 2026-02-16)
- Peptides.org|DSIP Dosage Calculator and Chart(accessed 2026-02-16)
Community Evidence Overview#
This page presents aggregated community protocols and anecdotal reports for DSIP (Delta Sleep-Inducing Peptide). The information below is gathered from peptide research forums, Reddit communities, and self-experimenter reports. This is not clinical evidence and should not be used as medical guidance.
DSIP was first identified in 1977 and has been the subject of limited human research, primarily conducted in the 1980s and 1990s. Community interest is driven by its reputation for promoting deep, restorative delta-wave sleep. However, the evidence base is limited, and the community protocols diverge significantly from the published research in both route and dosing.
Understanding Protocol Divergence#
Route of Administration#
The most significant divergence between clinical research and community use is the route of administration. Published DSIP studies used intravenous infusion, which provides rapid and complete systemic delivery. The community uses subcutaneous injection, a route with different absorption kinetics that has not been studied for DSIP. The pharmacokinetic profile of subcutaneously administered DSIP is unknown.
Dose Discrepancy#
Community doses (100-500 mcg SubQ) are substantially lower than the weight-based IV doses used in research (approximately 1,500-1,750 mcg for a 70 kg person). This large discrepancy could reflect the different route, community dose-finding through trial and error, or the finding that even lower doses produce subjective sleep effects. Without SubQ pharmacokinetic data, the relationship between community doses and clinically studied doses remains unclear.
Commonly Reported Outcomes#
Community members report the following effects from DSIP use:
- Sleep onset: Mild to moderate improvement in time to fall asleep, though DSIP is not typically described as a strong sedative
- Sleep depth: The most consistently reported benefit; users describe deeper, more restorative sleep with increased time in deep sleep phases
- Sleep duration: Some users report sleeping longer without middle-of-night awakenings
- Dream activity: Enhanced dream vividness is commonly reported
- Next-day effects: At appropriate doses, users report feeling more rested; overdosing commonly causes next-day grogginess
Important Caveats#
- DSIP research is dated, limited, and used different administration routes than community protocols
- Subjective sleep quality is highly susceptible to placebo effect
- Rebound insomnia after discontinuation has been reported by some users
- The long-term safety of repeated DSIP use is unknown
- Product purity is a concern as DSIP is only available from research peptide suppliers
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Frequently Asked Questions About DSIP
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.